LNCaP

From WikiMD's WELLNESSPEDIA

Human prostate cancer cell line

Overview[edit]

LNCaP cells under a microscope

LNCaP is a human prostate cancer cell line commonly used in cancer research. It was established from a metastatic lesion of human prostatic adenocarcinoma in the left supraclavicular lymph node of a 50-year-old Caucasian male. LNCaP cells are androgen-sensitive, meaning their growth is stimulated by androgens, which are male hormones such as testosterone.

Characteristics[edit]

LNCaP cells exhibit several key characteristics that make them valuable for research:

  • Androgen Sensitivity: LNCaP cells require androgens for optimal growth, making them a model for studying androgen-dependent prostate cancer.
  • PSA Production: These cells produce prostate-specific antigen (PSA), a protein used as a marker in prostate cancer diagnosis and monitoring.
  • Mutation Profile: LNCaP cells have a mutation in the androgen receptor gene, which affects their response to androgens.

Applications in Research[edit]

Comparison of various cancer cell lines, including LNCaP

LNCaP cells are widely used in prostate cancer research to:

  • Study the mechanisms of androgen receptor signaling and its role in prostate cancer progression.
  • Investigate the effects of anti-androgen drugs and other therapeutic agents.
  • Explore the molecular pathways involved in prostate cancer metastasis and resistance to therapy.

Comparison with Other Cell Lines[edit]

LNCaP cells are often compared with other prostate cancer cell lines such as PC-3 and DU145. Unlike LNCaP, PC-3 and DU145 are androgen-independent, meaning they do not require androgens for growth. This difference makes LNCaP particularly useful for studying the transition from androgen-dependent to androgen-independent prostate cancer.

Limitations[edit]

While LNCaP cells are a valuable tool in prostate cancer research, they have limitations:

  • Genetic Drift: Over time, LNCaP cells can undergo genetic changes that may affect experimental outcomes.
  • Limited Metastatic Potential: LNCaP cells have a lower metastatic potential compared to other cell lines, which may limit their use in studying advanced prostate cancer.

Related pages[edit]

See also[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=LNCaP&oldid=6340320"